erythromycin has been researched along with Familial Spastic Paraparesis, Htlv-1-Associated in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arimura, K; Higuchi, I; Izumo, S; Kawabata, M; Kubota, H; Maruyama, Y; Nakagawa, M; Nakahara, K; Osame, M | 1 |
| Araki, S; Ikeda, T; Kawasaki, S; Miyajima, M; Sugimoto, M; Uyama, E | 1 |
1 trial(s) available for erythromycin and Familial Spastic Paraparesis, Htlv-1-Associated
| Article | Year |
|---|---|
Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antiviral Agents; Ascorbic Acid; Azathioprine; Danazol; Erythromycin; Estrogen Antagonists; Female; Fosfomycin; Glycerol; Human T-lymphotropic virus 1; Humans; Hydrocortisone; Immunoglobulins, Intravenous; Immunosuppressive Agents; Injections, Intramuscular; Injections, Intravenous; Injections, Spinal; Interferon-gamma; Leukapheresis; Male; Methylprednisolone; Middle Aged; Paraparesis, Tropical Spastic; Pentoxifylline; Plasmapheresis; Propiophenones; Respiratory Therapy; Ribonucleosides; Sulfasalazine; Thyrotropin-Releasing Hormone; Vasodilator Agents | 1996 |
1 other study(ies) available for erythromycin and Familial Spastic Paraparesis, Htlv-1-Associated
| Article | Year |
|---|---|
[A case of HTLV-1 associated myelopathy progressed in course over 30 years].
Topics: Aged; Atrophy; Brain; Erythromycin; Female; HTLV-I Antibodies; Humans; Magnetic Resonance Imaging; Paraparesis, Tropical Spastic; Time Factors; Tomography, X-Ray Computed | 1991 |